Showing results (41-50 of 181) with videos related to

Sort By:
Pageof 19
Pharmacogenetics and Genomics|August 11, 2016
Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by racePaul Leger, Sanika Chirwa, Megan Turner, et al.
Plos Pathogens|May 1, 2007
Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infectionKyra Oswald-Richter, Stacy M Grill, Mindy Leelawong, et al.
Pharmacogenetics and Genomics|July 7, 2015
Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202Valentine Wanga, Charles Venuto, Gene D Morse, et al.
The Journal of Antimicrobial Chemotherapy|April 15, 2014
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypesDavid W Haas, Awewura Kwara, Danielle M Richardson, et al.
AIDS (London, England)|September 28, 2010
European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142Todd Hulgan, Richard Haubrich, Sharon A Riddler, et al.
The Journal of Antimicrobial Chemotherapy|August 29, 2022
Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African populationRulan Griesel, Phumla Sinxadi, Aida Kawuma, et al.
Summit on Translational Bioinformatics|February 25, 2011
An automated approach to calculating the daily dose of tacrolimus in electronic health recordsHua Xu, Son Doan, Kelly A Birdwell, et al.
The Journal of Antimicrobial Chemotherapy|December 12, 2018
Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolitesEric H Decloedt, Phumla Z Sinxadi, Gert U van Zyl, et al.
Journal of Clinical Microbiology|July 5, 2003
Major outbreak of toxic shock-like syndrome caused by Streptococcus mitisHong-Zhou Lu, Xin-Hua Weng, Bai Zhu, et al.
Pageof 19